摘要
目的探讨调肝理脾化积方联合高强度聚焦超声(HIFU)对局部晚期胰腺癌患者临床疗效。方法采用随机、平行对照,选取局部晚期胰腺癌患者60例,采用随机数字表法分为治疗组和对照组各30例。治疗组予调肝理脾化积方,每日1剂,每日2次,口服,28 d为1个疗程,共6个疗程;同时予HIFU,每次30~60 min,隔日1次,每周2~3次,将肿瘤完全覆盖2遍。对照组予吉西他滨1000 mg/m^2,静脉滴注,第1、8日,21~28 d为1个周期,共6个周期。观察2组临床受益反应、生活质量QOL-C30评分、生存情况、无进展生存期(PFS),检测CA199、CEA水平。结果治疗1、3、6个月临床受益率,治疗组分别为64.29%、63.16%、50.00%,对照组分别为48.15%、40.00%、44.44%,治疗1、3个月2组比较差异有统计学意义(P<0.05)。治疗1、3、6个月,2组同一时点QOL-C30评分比较差异有统计学意义(P<0.05)。治疗1~6个月,2组CA199呈下降趋势,差异无统计学意义(P>0.05)。治疗组同一时点CEA水平均低于对照组(除治疗2、6个月),差异有统计学意义(P<0.05)。治疗3、6、12个月,治疗组生存率分别为82.14%、46.42%、32.14%,对照组分别为96.67%、59.32%、37.04%,2组比较差异无统计学意义(P>0.05)。1年时治疗组生存时间为(253.90±18.06)d,对照组为(246.77±17.31)d,2组比较差异无统计学意义(P>0.05)。治疗组PFS为(136.73±16.22)d,对照组为(145.77±19.74)d,2组比较差异无统计学意义(P=0.801)。结论调肝理脾化积方联合聚焦超声治疗局部晚期胰腺癌具有一定临床效果,可提高患者生活质量。
Objective To investigate the effects of Tiaogan Lipi Huaji Prescription combined with high intensity focused ultrasound （HIFU） for the treatment of locally advanced pancreatic cancer. Methods Randomized, parallel controlled study was designed to select 60 patients with locally advanced pancreatic cancer, which were divided into treatment group and control group by random number table method, 30 cases in each group. The treatment group was given Tiaogan Lipi Huaji Prescription, one dose per day, twice a day, orally, 28 d as a treatment course, 6 courses in total; at the same time, HIFU was given to the treatment group, 30–60 min each time, once every other day, 2–3 times each week, and the tumor was completely covered for 2 times. The control group was given gemcitabine 1000 mg/m2, intravenous infusion, 1st, 8th d, 21–28 d for a cycle, a total of 6 cycles. The clinical benefit response, QOL-C30 score, survival status, progression-free survival （PFS）, CA199 and CEA levels were observed. Results Clinical benefit rates of treatment group and control group were： the treatment group 1, 3, 6 months clinical benefit rate was 64.29%, 63.16%, and 50.00%, respectively; control group clinical benefit rate was 48.15%, 40.00%, and 44.44%, respectively, with statistical significance （P〈0.05）. The difference of QOL-C30 score between the two groups at the same time wasstatistically significant （P〈0.05）. During the treatment 1 to 6 months, CA199 in the two groups showed a downward trend, without statistical significance （P〉0.05）. CEA levels in the treatment group were lower than those in the control group at the same time with statistical significance （P〈0.05）, except for 2 and 6 months. The survival rates of treatment of 3, 6, and 12 months in the treatment group were 82.14%, 46.42% and 32.14%, respectively, and were 96.67%, 59.32% and 37.04%, respectively in the control group, without statistical significance （P〉0.05）. The survival time of the treatment group was （253.90±18.06）d in the control group and （246.77±17.31）d in the control group, without statistical significance （P〉0.05）. PFS was （136.73±16.22）d in the treatment group and （145.77±19.74）d in the control group, without statistical significance （P〉0.05）. Conclusion Tiaogan Lipi Huaji Prescription combined with HIFU for the treatment of locally advanced pancreatic cancer has certain clinical efficacy, which can improve patients’ life quality.
出处
《中国中医药信息杂志》
CAS
CSCD
2017年第7期23-27,共5页
Chinese Journal of Information on Traditional Chinese Medicine
基金
首都市民健康项目(Z141100002114028)
北京市卫生系统高层次卫生技术人才培养计划(2015-3-115)
关键词
局部晚期胰腺癌
高强度聚焦超声
无进展生存期
生存率
临床受益反应
locally advanced pancreatic cancer
high intensity focused ultrasound
progression-free survival
survival rate
clinical benefit response
